IDH1 and central nervous system cancer: In addition to IDH1/2, 1p/19q, MGMT, hTERT, TP53, PTEN, EGFR, and ATRX, which were investigated here, we plan to evaluate other genetic markers related to glioma characteristics and prognosis, as well as those recognized as therapeutic and immune targets.